CHEK2 and cancer: Approximately 11% to 17% of patients with metastatic PCa have been reported to have germline mutations in key hereditary cancer genes, including BRCA2, ATM, CHEK2, BRCA1, RAD51D, or PALB2 [2-4], which represents a substantial population burden.